Tilsotolimod

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameTilsotolimod
Drug Alias NameIMO-2125
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionToll like receptor 9 agonists
TargetsToll like receptor 9
Therapy Area/IndicationsSolid tumoursMelanomaHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[13] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAceragen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAceragen Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsMelanomaHepatitis C

Other Information

ATC CodeN/A
Related LinksN/A